Speed and access beat small sensitivity gains in community TB screening

Tuberculosis remains a global health challenge, and programs that actively seek out undiagnosed cases in communities are expensive and operationally difficult. Current active case-finding (ACF) efforts are constrained by the cost, how easily people can provide specimens, how quickly results come back, and how sensitive confirmatory tests are. To clarify which of these constraints matters most for public health impact, Lukas E. Bruemmer and colleagues built an epidemiological model to simulate a one-time, community-based ACF intervention operating on a fixed budget of one million United States dollars. The model assumed an adult population with four times the national prevalence of Uganda and compared outcomes when the program used a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus versions of an improved confirmatory test. The research aimed to identify which improvements to a confirmatory test—higher sensitivity, non-sputum specimens, faster result delivery, or lower cost—would most increase diagnoses, prevent deaths, and reduce transmission, given realistic budget and operational constraints.

The model examined a simulated target population of 400,000 adults. In the absence of ACF, the model estimated 6,421 people would have TB disease (1.6%; 95% uncertainty range 5,316–7,531) and 873 people (612–1,182) would die of TB. Under current confirmatory-test performance, the one-time ACF intervention could reach 83,808 people (59,388–118,601; 21% of the target population) within the allotted budget, linking 651 people with TB (429–983) to treatment and averting 76 deaths (39–132). The team evaluated four hypothetical test improvements: increased sensitivity (from 69% to 80%), non-sputum specimen use (raising specimen availability from 93% to 100%), immediate turn-around of results (increasing delivery of positive results from 91% to 100%), and reduced cost (from $20 to $9 per confirmatory test). Higher diagnostic sensitivity produced the largest increase in the number of people with TB who received treatment (14% increase; 4–26%), while tests that provided immediate turn-around yielded the largest reductions in mortality or transmission (11% reduction; 5–18%). Outcomes for people not reached by ACF were guided by recent natural history models of routine care.

The findings point to a practical message for test developers and public health planners: within the constraints of a fixed budget and a one-time community campaign, making confirmatory tests faster and more accessible may deliver larger population benefits than small gains in sensitivity alone. Immediate return of positive results and removing barriers to specimen collection (for example, non-sputum sampling) directly boost the number of people successfully diagnosed and treated, and reduce onward transmission, because they improve the pathway from screening to care. At the same time, the study makes clear that changes to the confirmatory diagnostic alone are unlikely to produce very large (>20%) increases in health impact; achieving that scale of improvement will require enhancements to other parts of ACF programs beyond just the test. These results—derived from the model developed by Lukas E. Bruemmer and colleagues—offer a data-driven way to prioritize investments aimed at maximizing lives saved and transmission averted in community TB screening.